PainRelief.com: What are the main findings?

Response: The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1300 milligrams, taken at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including some, but not all, randomized trials, suggests the possibility that daily aspirin in doses from 81 to 325 milligrams, may be an effective and safe treatment option for the prevention of recurrent migraine headaches. 

PainRelief.com: What should readers take away from your report?

Response: The relatively favorable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers treating acute as well as recurrent migraine headaches.

PainRelief.com: What recommendations do you have for future research as a result of this work?

Response: Future randomized trials may wish to consider aspirin as a safe, effective, low cost comparator drug.

Disclosures

Bianca Biglione and Alexander Gitin report no disclosures. Professor Gorelick discloses that he or his employer Thorek Memorial Hospital receives honoraria for his role as a member of  Steering or Adjudication Committees as well as Data and Safety Monitoring Boards.    Professor Hennekens  discloses that he serves as an independent scientist in an advisory role to investigators and sponsors as Chair or Member of Data and Safety Monitoring Boards for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, Regeneron and the Wellcome Foundation; to the United States (U.S.) Food and Drug Administration and UpToDate;  receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women’s Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority and does not own any common or preferred stock in any pharmaceutical or medical device company.

Citation:

Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. The American Journal of Medicine, 2019; DOI: 10.1016/j.amjmed.2019.10.023

[wysija_form id=”3″]

[last-modified]

The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

EDITORS’ NOTE: DO NOT BEGIN AN ASPIRIN PROGRAM WITHOUT THE ADVICE AND DIRECTION OF YOUR HEALTH CARE PROVIDER.

Last Updated on December 4, 2019 by PainRelief.com